AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
Lexicon Pharmaceuticals (NASDAQ:LXRX) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market ...
Reports indicate that Stifel analyst Erik Rasmussen raised his estimated valuation of the New Zealand rocket-maker by more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback